Athena Neurosciences Inc.
Division of Perrigo Co. PLC
Latest From Athena Neurosciences Inc.
Perrigo Faces $370m Tax Payment From Second IRS Audit Linked To Elan Deal
IRS Notice Pushes Perrigo's Potential Tax Debt From Move To Ireland Close To $3bn
IRS tax assessment for 2013, the year Perrigo acquired Dublin-based Elan, adds another cloud to OTC private label giant's outlook as it prepares to present plans for accelerating growth for its long-slumping consumer health business in the US and Europe at a March 9 investor day conference. Perrigo shares dropped more than 9% in early trading after IRS notice became known to investors before inching upward and ending at $47.92, down 6.8% from the previous day's close.
Biogen Defends its Specialist Market
Shire Shifts Upstream
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Perrigo Co. PLC
- Senior Management
-
David Johnson, VP, Fin. & CFO
Michael Coffee, Pres. & COO
Heidi Horner, VP, Bus. Dev. & Project Planning
Lloyd Glenn, VP, Mktg.
Ivan M Lieberburg, MD, PhD, VP, Research - Contact Info
-
Athena Neurosciences Inc.
Phone: (415) 877-0900
800 Gateway Boulevard
S. San Francisco, CA 94080-
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice